share_log

Prime Medicine (NYSEARCA:PRME) Shares Up 7.4%

Prime Medicine (NYSEARCA:PRME) Shares Up 7.4%

Prime Medicine(NYSEARCA：PRME)股價上漲7.4%
Financial News Live ·  2022/12/01 23:21

Prime Medicine, Inc. (NYSEARCA:PRME – Get Rating)'s stock price shot up 7.4% during trading on Tuesday . The stock traded as high as $18.79 and last traded at $18.73. 7,198 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 235,939 shares. The stock had previously closed at $17.44.

Prime Medicine，Inc.(NYSEArca：PRME-GET Rating)股價週二大漲7.4%，盤中一度漲至18.79美元，最新報18.73美元。午盤時有7,198股易手，較235,939股的平均成交量下跌97%。該股此前收盤報17.44美元。

Analyst Ratings Changes

分析師評級發生變化

Several research firms have commented on PRME. The Goldman Sachs Group began coverage on shares of Prime Medicine in a research note on Monday, November 14th. They issued a "neutral" rating and a $22.00 price target for the company. Jefferies Financial Group began coverage on shares of Prime Medicine in a research report on Monday, November 14th. They set a "buy" rating and a $25.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of Prime Medicine in a research report on Monday, November 14th. They set an "overweight" rating and a $27.00 price objective for the company. Finally, Morgan Stanley began coverage on shares of Prime Medicine in a research report on Monday, November 14th. They set an "equal weight" rating and a $23.00 price objective for the company.

幾家研究公司對PRME發表了評論。11月14日，週一，高盛在一份研究報告中開始對優質醫藥的股票進行報道。他們對該公司的評級為“中性”，目標價為22.00美元。傑富瑞金融集團於11月14日(星期一)在一份研究報告中開始報道Prime Medicine的股票。他們為該公司設定了“買入”評級和25.00美元的目標價。摩根大通公司在11月14日星期一的一份研究報告中開始對Prime Medicine的股票進行報道。他們為該公司設定了“增持”評級和27.00美元的目標價。最後，摩根士丹利在11月14日星期一的一份研究報告中開始了對優質醫藥股票的報道。他們為該公司設定了“同等權重”的評級和23.00美元的目標價。

Get
到達
Prime Medicine
優質醫療
alerts:
警報：

Prime Medicine Stock Down 0.8 %

Prime Medicine股價下跌0.8%

The business's fifty day moving average price is $19.27 and its 200 day moving average price is $19.89.

該業務的50日移動均線價格為19.27美元，200日移動均線價格為19.89美元。

Insider Transactions at Prime Medicine

Prime Medicine的內幕交易

In related news, Director Thomas Cahill bought 400,000 shares of the stock in a transaction on Monday, October 24th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $6,800,000.00. Following the completion of the transaction, the director now owns 5,305,679 shares of the company's stock, valued at approximately $90,196,543. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through
在相關新聞中，董事託馬斯·卡希爾在10月24日(星期一)的一次交易中購買了40萬股該股。這些股票是以每股17.00美元的平均成本購買的，總交易額為6800,000.00美元。交易完成後，董事現在擁有該公司5,305,679股股票，價值約90,196,543美元。此次收購是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過以下方式獲取
this link
這個環節
. In related news, Director Thomas Cahill bought 400,000 shares of the stock in a transaction on Monday, October 24th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $6,800,000.00. Following the completion of the transaction, the director now owns 5,305,679 shares of the company's stock, valued at approximately $90,196,543. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through
。在相關新聞中，董事託馬斯·卡希爾在10月24日(星期一)的一次交易中購買了40萬股該股。這些股票是以每股17.00美元的平均成本購買的，總交易額為6800,000.00美元。交易完成後，董事現在擁有該公司5,305,679股股票，價值約90,196,543美元。此次收購是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過以下方式獲取
this link
這個環節
. Also, major shareholder 2019 Gp L.L.C. Gv bought 800,000 shares of the stock in a transaction on Monday, October 24th. The shares were bought at an average price of $17.00 per share, for a total transaction of $13,600,000.00. Following the completion of the transaction, the insider now directly owns 11,522,248 shares of the company's stock, valued at approximately $195,878,216. The disclosure for this purchase can be found
。此外，大股東2019 GP L.L.C.GV在10月24日(星期一)的交易中購買了80萬股該股。這些股票是以每股17.00美元的平均價格購買的，總交易額為13,600,000.00美元。交易完成後，該內部人士現在直接擁有該公司11,522,248股股票，價值約195,878,216美元。關於這次購買的披露可以找到
here
這裏
.
.

Prime Medicine Company Profile

優質醫藥公司簡介

(Get Rating)

(獲取評級)

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.

Prime Medicine，Inc.是一家生物技術公司，通過部署基因編輯技術提供基因療法來治療疾病。它為Prime Edants提供了Prime Editor蛋白質和pegRNA，前者包括CaS蛋白質和逆轉錄酶之間的融合；後者將Prime Editing定位於特定的基因組位置，並提供對目標DNA序列進行所需編輯的模板。

Featured Stories

專題報道

  • Get a free copy of the StockNews.com research report on Prime Medicine (PRME)
  • Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
  • Santa Claus Rally? Here's What Needs to Happen
  • Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
  • Dark Clouds Are Gathering For Cloud Stocks
  • 3 Dividend Growers With Good 2023 Growth Prospects
  • 免費獲取StockNews.com關於Prime Medicine(PRME)的研究報告
  • 放寬Covid規則會降低中國電動汽車製造商蔚來的風險嗎？
  • 聖誕老人拉力賽？以下是需要發生的事情
  • Cosmos Holdings可能是具有短期風險的長期買入
  • 烏雲雲集，雲股雲集
  • 3個具有良好2023年增長前景的股息增長者

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

接受《頂級醫學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Prime Medicine和相關公司的最新新聞和分析師評級的每日簡要摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論